Barrett & Company Inc. Has $45,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Barrett & Company Inc. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90 shares of the company’s stock after selling 70 shares during the period. Barrett & Company Inc.’s holdings in IDEXX Laboratories were worth $45,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Baker Tilly Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $221,000. J.W. Cole Advisors Inc. increased its position in IDEXX Laboratories by 98.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 2,642 shares of the company’s stock valued at $1,335,000 after acquiring an additional 1,310 shares during the period. Clear Harbor Asset Management LLC raised its stake in shares of IDEXX Laboratories by 2.7% during the third quarter. Clear Harbor Asset Management LLC now owns 8,020 shares of the company’s stock valued at $4,052,000 after acquiring an additional 212 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of IDEXX Laboratories by 1.1% during the third quarter. DekaBank Deutsche Girozentrale now owns 54,792 shares of the company’s stock worth $27,892,000 after purchasing an additional 572 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of IDEXX Laboratories by 197.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 29,634 shares of the company’s stock worth $14,972,000 after purchasing an additional 19,659 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.8 %

Shares of NASDAQ IDXX traded up $3.42 during mid-day trading on Monday, reaching $454.83. 92,798 shares of the company’s stock traded hands, compared to its average volume of 475,265. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The stock has a market cap of $37.56 billion, a P/E ratio of 43.70, a PEG ratio of 4.03 and a beta of 1.33. The business has a 50-day simple moving average of $484.62 and a 200 day simple moving average of $489.21.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business earned $2.67 EPS. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. On average, analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on IDXX shares. Piper Sandler reduced their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. BTIG Research initiated coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.